Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI (PARADISE-MI)

NCT02924727 PHASE3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE3
Status	COMPLETED
Enrolment	5669
Start date	Fri Dec 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Feb 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acute Myocardial Infarction

Interventions

• LCZ696 (sacubitril/valsartan)
• Ramipril
• Placebo of LCZ696
• Placebo of ramipril
• Valsartan
• Placebo of valsartan

Countries

Italy, Colombia, Finland, Taiwan, Poland, South Korea, Philippines, Croatia, Denmark, Netherlands, Russia, Belgium, Sweden, Mexico, Thailand, Bulgaria, Czechia, Portugal, United States, France, South Africa, Slovakia, Greece, Austria, Israel, Hungary, Norway, Argentina, Canada, Romania